Celldex Therapeutics (CLDX) EBT Margin (2016 - 2025)
Historic EBT Margin for Celldex Therapeutics (CLDX) over the last 16 years, with Q2 2025 value amounting to 7753.42%.
- Celldex Therapeutics' EBT Margin fell 63186000.0% to 7753.42% in Q2 2025 from the same period last year, while for Sep 2025 it was 8635.85%, marking a year-over-year decrease of 70913700.0%. This contributed to the annual value of 2248.76% for FY2024, which is 1940000.0% down from last year.
- According to the latest figures from Q2 2025, Celldex Therapeutics' EBT Margin is 7753.42%, which was down 63186000.0% from 7740.43% recorded in Q1 2025.
- In the past 5 years, Celldex Therapeutics' EBT Margin registered a high of 384.28% during Q2 2021, and its lowest value of 22088.34% during Q2 2022.
- Its 5-year average for EBT Margin is 7065.57%, with a median of 5020.08% in 2021.
- In the last 5 years, Celldex Therapeutics' EBT Margin tumbled by -217040600bps in 2022 and then surged by 132903400bps in 2025.
- Celldex Therapeutics' EBT Margin (Quarter) stood at 6032.34% in 2021, then skyrocketed by 73bps to 1642.1% in 2022, then surged by 36bps to 1048.32% in 2023, then plummeted by -282bps to 4007.83% in 2024, then plummeted by -93bps to 7753.42% in 2025.
- Its EBT Margin was 7753.42% in Q2 2025, compared to 7740.43% in Q1 2025 and 4007.83% in Q4 2024.